Texas Tech University Health Sciences Center (TTUHSC) and Deep 6 AI announced a collaboration, collaborating to integrate artificial intelligence (AI) within TTUHSC's electronic medical record (EMR) system.
TTUHSC will use Deep 6 AI to match patients to their clinical trials in real time. This process will allow researchers to find the right patients for their trials, which will reduce the workload on their staff. By using these AI tools, TTUHSC researchers will ultimatey give more patients access to participate in clinical trials and will be able to use any resulting therapies to treat patients.
Deep 6 AI uses natural language processing to search through structured and unstructured EMR data points, such as physician notes, lab reports, outpatient notes, radiology reports, genomics results, and pathology reports, to match patients to the ideal clinical trials. This process simplifies patient recruitment and allows administrators to focus on patient care and managing the trials.
Texas Tech University Health Sciences Center Partners with Deep 6 AI to Launch an AI Program for Clinical Trials. (2023, August 1). Cision PR Newswire.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.